Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016


Posted on: 24 Aug 16

Valby, Denmark, 2016-08-24 07:51 CEST (GLOBE NEWSWIRE) -- HIGHLIGHTS

  • Revenue reached DKK 7,521 million in the first half of 2016 representing an increase of 5% in both reported and local currencies compared to the same period last year
    • Total revenue has delivered a better performance than expected driven by Xenazine® and key products
    • US revenue increased 33% (31% in local currency) to DKK 3,840 million
    • Revenue in International Markets declined 5% (unchanged in local currencies) to DKK 2,033 million
    • Europe declined 26% (25% in local currencies) to DKK 1,453 million
  • Revenue from key products grew 99% (99% in local currencies) to DKK 2,902 million in the period representing 39% of total revenue
    • Abilify Maintena® sees strong growth reaching DKK 534 million. The growth of 93% (94% in local currencies) was driven by all regions, but particularly by Europe
    • Brintellix®/Trintellix sales grew 103% and reached DKK 482 million, with non-US markets contributing DKK 220 million or 46% of total Brintellix sales
    • Northera® sales reached DKK 449 million, up 203% (201% in local currency)
    • Onfi® continues its solid performance growing 42% (40% in local currency) to DKK 1,128 million
    • Rexulti® was launched in the US in August 2015 and revenue reached DKK 309 million  
  • In the first half of 2016, the EBIT-margin reached 12.7% compared to a negative margin of 67.6% in the same period in 2015. In 2015, EBIT included an impairment loss of DKK 4.8 billion
  • Following the solid performance, Lundbeck now expects revenue of around DKK 14.6-15.0 billion and EBIT is expected to reach DKK 1.5-1.7 billion for 2016 compared to previously DKK 14.2-14.6 billion and DKK 1.3-1.5 billion, respectively

 

In connection with the financial report, Lundbeck’s President and CEO, Kåre Schultz said:

“I am very pleased with the continued strong sales growth of our key products and the increase of our financial guidance. We are on track to improve our profitability and I am excited about our R&D pipeline.”

 

DKK million H1 2016  H1 2015 Growth
Reported Revenue 7,521 7,192 5%
Reported EBIT 952 (4,865) -
Reported EPS 2.12 (20.26) -
Reported EBIT margin 12.7% (67.6%) -
       
Core Revenue* 7,521 7,192 5%
Core EBIT* 1,475 351 320%
Core EBIT margin* 19.6% 4.9% 300%

*For definition of the measures “Core Revenue” and “Core EBIT”, see note 3 Core reporting

GlobeNewswire
globenewswire.com

Last updated on: 25/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.